Diana Ernst, RPh

Editorial Director https://www.rheumatologyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Pediatric Rheumatology

Actemra SC Approved to Treat Active Systemic JIA

Diana Ernst, RPh

September 14, 2018

The FDA has approved Actemra SC for the treatment of active systemic JIA alone or in combination with methotrexate in patients ≥2 years old.

Osteoarthritis

Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab

Diana Ernst, RPh

July 18, 2018

Pfizer and Lilly announced positive results from a study evaluating tanezumab, an investigational humanized monoclonal antibody, for the treatment of OA pain.

Rheumatoid Arthritis

Antibiotic-Methotrexate Combination Leads to Serious Side Effects in a Patient With RA

Diana Ernst, RPh

June 25, 2018

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10 mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of trimethoprim-sulfamethoxazole for a bacterial skin infection.

Spondyloarthritis

FDA: Secukinumab Slows Progression of Joint Structural Damage in Psoriatic Arthritis

Diana Ernst, RPh

June 21, 2018

The FDA has approved updated labeling for Cosentyx that includes data demonstrating that the drug slows the progression of joint structural damage in patients with active psoriatic arthritis.